TrialClinical cancer research : an official journal of the American Association for Cancer Research2024

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

Michael I Barbato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.